Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 13/20 | 0.43 |
| ▸ | EZH2 | Q15910 | 3/20 | 0.37 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14727079 | 0.86 | EZH2 (0.40) | EZH2EZH1FFAR4MAPTNR4A2 | |
| SCHEMBL14917583 | 0.80 | EZH2 (0.42) | ERN1EZH2EZH1FFAR4ALDH1A1 | |
| SCHEMBL2588982 | 0.75 | EZH2 (0.40) | EZH2EZH1NR4A2 | |
| SCHEMBL2587259 | 0.74 | CA12 (0.37) | EZH2ALDH1A1MAPTPOLB | |
| SCHEMBL2587361 | 0.72 | CA12 (0.35) | EZH2ALDH1A1MAPTNR4A2 | |
| SCHEMBL12180129 | 0.71 | EZH2 (0.41) | EZH2EZH1FFAR4 | |
| SCHEMBL2594904 | 0.70 | ERN1 (0.35) | ERN1ALDH1A1MAPTPOLBRAB9A | |
| SCHEMBL2592122 | 0.70 | CA12 (0.36) | EZH2EZH1 | |
| SCHEMBL2592384 | 0.69 | LMNA (0.38) | EZH2EZH1ALDH1A1 | |
| SCHEMBL27979669 | 0.68 | PDGFRB (0.33) | EZH2EZH1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160296518-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160296518-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| US-9446041-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9446041-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| EP-2773754-B1 | Compounds for use in the treatment of T-cell mediated diseases | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-08-03 | — | — | EP | disclosed |
| US-9402836-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20130345200-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2013-12-26 | — | — | US | disclosed |
| US-8536179-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536179-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2013067296-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067296-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| EP-2566327-A1 | INDOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345200-A1 | INDOLES | IDO1, IDO2, INMT | ERN1 4312/4885EZH2 257/4885EZH1 669/4885 |
| US-20130053397-A1 | INDOLES | IDO1, IDO2, INMT | ERN1 4362/4885EZH2 239/4885EZH1 677/4885 |
| US-20160296518-A1 | INDOLES | IDO1, IDO2, INMT | ERN1 4312/4885EZH2 257/4885EZH1 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.